Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dietex Forte is an oral weight management medication developed by Kramer Novis. The product's primary active ingredient is benzocaine, a local anesthetic. Benzocaine functions as an appetite suppressant by numbing the oral mucosa and taste buds, thereby reducing the sensory appeal of food and the urge to eat. The formulation typically includes methylcellulose, which serves as a bulking agent to increase satiety by promoting a feeling of fullness in the stomach. Dietex Forte is marketed for the treatment of obesity and as an aid in weight loss programs, particularly in the Puerto Rican market. While benzocaine was historically included in over-the-counter weight loss monographs in the United States, its status for this specific indication has been subject to regulatory changes over time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dietex Forte.